Liquidia Technologies has named Jeri Thomas as its new Senior VP Commercial, responsible initially for commercial plans for the company’s LIQ861 treprostinil DPI, which is currently in Phase 3 development for the treatment of pulmonary arterial hypertension (PAH).
According to Liquidia, Thomas was most recently Senior VP, Strategic Group Planning at healthcare marketing agency Harrison and Star. She has also held various management positions at The Medicines Company, Janssen Pharmaceuticals, Bristol-Myers Squibb and Hoffman-La Roche.
Thomas commented, “I am impressed and excited with the team’s commitment to improving the quality of life for those living with PAH. The innovative design of LIQ861 to enable deep-lung delivery and to safely deliver higher doses into the lungs has the potential to overcome the limitations of current nebulized therapies. Liquidia is positioned for the next stage of growth with LIQ861 in late-stage development and I look forward to playing a role in its success.”
Liquidia CEO Neal Fowler said, “Jeri brings an extensive background in building and leading commercial organizations. As we look to advance LIQ861 for the treatment of PAH, having her expertise will be critical to the development and leadership of our commercialization strategy. She is a leader within the industry and we are excited to have her onboard.”
Read the Liquidia press release.
